Jon Congleton Sells 18,333 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton sold 18,333 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.06, for a total value of $166,096.98. Following the sale, the chief executive officer now owns 877,608 shares in the company, valued at $7,951,128.48. The trade was a 2.05 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $9.50 on Friday. Mineralys Therapeutics, Inc. has a 52-week low of $7.95 and a 52-week high of $16.91. The stock has a market cap of $472.81 million, a price-to-earnings ratio of -2.91 and a beta of 1.49. The firm’s 50-day moving average is $12.27 and its 200-day moving average is $12.47.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same quarter in the prior year, the business earned ($0.57) earnings per share. Sell-side analysts predict that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday, November 12th.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MLYS. SG Americas Securities LLC acquired a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth about $110,000. China Universal Asset Management Co. Ltd. lifted its position in Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock worth $116,000 after acquiring an additional 3,732 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Mineralys Therapeutics by 100.0% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after acquiring an additional 6,000 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Mineralys Therapeutics during the second quarter worth approximately $145,000. Finally, PDT Partners LLC acquired a new position in shares of Mineralys Therapeutics in the third quarter valued at approximately $148,000. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.